핵산 추출 및 정제 시장 예측(-2030년) : 제품별, 방법별, 유형별, 샘플 유형별, 용도별, 최종사용자별, 지역별

The nucleic acid isolation and purification market is expected to grow from USD 7.10 billion in 2025 to USD 10.99 billion in 2030, at a CAGR of 9.1% during the forecast period.

PCR and other NAAT workflows are routine in many infectious disease programs. Labs are expanding test menus and handling higher sample volumes. NGS is also moving deeper into clinical use cases, increasing the need for clean DNA/RNA as a first step. Declining extraction quality affects downstream sensitivity. This encourages end users to continue investing in reliable NAIP workflows and reagents.

"The magnetic-bead based isolation and purification segment accounted for the largest share, by method, in the nucleic acid isolation and purification market in 2024."

The nucleic acid isolation and purification market is segmented into magnetic bead-based isolation and purification, column-based isolation and purification, reagent-based isolation and purification, and other methods. In 2024, the magnetic bead-based isolation and purification method dominated the market. This dominance is driven by the compatibility of bead workflows with automation and high-throughput processing, which are priorities for hospitals, reference labs, and large research centers. Bead-based methods also deliver consistent yields and reproducibility across batches, helping labs reduce reruns and maintain turnaround times.

"The diagnostics segment was the largest application segment in the nucleic acid isolation and purification market in 2024."

The nucleic acid isolation and purification market is segmented by application into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. The diagnostics segment led the market in 2024. The primary reason is that DNA/RNA extraction is a necessary first step for most PCR/NAAT assays. In addition, a growing number of sequencing-based clinical tests is supporting expansion. High routine volumes from infectious disease panels, respiratory testing, and oncology molecular assays maintain steady demand. Diagnostic labs also prioritize standardized and validated workflows to reduce variability, avoid reruns, and shorten turnaround times.

"The Asia Pacific region will grow at the highest CAGR in the nucleic acid isolation and purification market from 2025 to 2030."

The Asia Pacific region is estimated to be the fastest-growing segment of the market. This growth is supported by the expansion of population genomics programs and the rising focus on precision medicine. The region is also seeing increased demand for diagnosis and monitoring of rare and genetic diseases, especially in aging populations in markets such as Japan and China. As a result, sequencing and other molecular testing are being adopted more widely in routine healthcare.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 40%, Tier 2- 30% and Tier 3- 30%
• By Designation: Directors- 20%, Managers- 10% and Others - 70%,
• By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Promega Corporation (US)
• Agilent Technologies, Inc. (US)
• Danaher(US)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Takara Bio Inc. (Japan)
• New England Biolabs (US)
• Abcam Plc (UK)
• KILPEST India Limited (India)
• Apical Scientific Sdn. Bhd. (Malaysia)
• Endress+Hauser Group Services AG (Switzerland)
• GENAXXON bioscience GmbH (Germany)
• LGC Biosearch Technologies (US)
• Zymo Research Corporation (US)
• Norgen Biotek Corp. (Canada)
• Omega Bio-Tek, Inc. (US)
• FAVORGEN Biotech Corp. (China)
• TIANGEN Biotech (Beijing) Co., Ltd. (China)
• AutoGen Inc. (US)
• PCR Biosystems (UK)
• Biogenuix (India)

Research Coverage

This research report categorizes the nucleic acid isolation and purification market by product [Kits, Reagents, Instruments (Manual, Automatic)], by type (Plasmid DNA isolation and purification, Total RNA isolation and purification, Genomic DNA isolation and purification, Messenger RNA isolation and purification, Circulating nucleic acid isolation and purification, MicroRNA isolation and purification, Other types), by method (Magnetic bead-based isolation and purification, Reagent-based isolation and purification, Column-based isolation and purification, Other methods), by application (Diagnostics, Drug discovery & development, Personalized medicine, Agriculture and animal research, Other applications), by end user (Hospitals and diagnostic centers, Academic and government research institutes, Pharmaceutical and biotechnology companies, Contract Research Organizations (CROs), Other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the nucleic acid isolation and purification market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolio, key strategies such as product launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the nucleic acid isolation and purification market. Competitive analysis of top players and upcoming startups in the nucleic acid isolation and purification market ecosystem is also covered in this report.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall nucleic acid isolation and purification market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

Analysis of key drivers (routine PCR/qPCR and NGS testing scaling across care and research, expanding public health genomic surveillance in more countries), restraints (high cost and time required for high-volume testing), opportunities (automation impacting throughput, traceability, and staffing resilience, premium NAIP products for cfDNA, oncology, and low-input workflows), and challenges (variability due to PCR inhibitors and matrix effects) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products of the nucleic acid isolation and purification market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nucleic acid isolation and purification market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Danaher(US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Takara Bio Inc. (Japan), New England Biolabs (US), Abcam Plc (UK), KILPEST India Limited (India), Apical Scientific Sdn. Bhd. (Malaysia), Endress+Hauser Group Services AG (Switzerland), GENAXXON bioscience GmbH (Germany), and LGC Biosearch Technologies (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
• 1.4 INCLUSIONS & EXCLUSIONS
  • 1.4.1 YEARS CONSIDERED
  • 1.4.2 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET OVERVIEW
• 3.2 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT
• 3.3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY END USER, 2026 VS 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising adoption of automated nucleic acid extraction systems
    • 4.2.1.2 Increasing need for high-purity and inhibitor-free nucleic acid recovery
    • 4.2.1.3 Broadening use of magnetic bead-based purification chemistries
    • 4.2.1.4 Growth in complex and difficult sample-type processing
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Price pressure and partial commoditization of routine extraction kits
    • 4.2.2.2 Continued use of manual and low-cost in-house methods in small & mid-sized labs
    • 4.2.2.3 Workflow substitution in selected use cases
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Premium extraction solutions for low-input and cell-free nucleic acids
    • 4.2.3.2 Expansion of automated benchtop and mid-throughput extraction platforms
    • 4.2.3.3 Workflow integration with quantitation, tracking, and digital reporting
    • 4.2.3.4 Application-specific extraction workflows in biopharma and CGT
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Pre-analytical variability that affects extraction output
    • 4.2.4.2 Removal of inhibitors and contaminants from difficult matrices
    • 4.2.4.3 Standardization and validation for regulated or sensitive workflows
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
  • 5.2.4 TRENDS IN HEALTHCARE EXPENDITURE
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
• 5.6 PRICING ANALYSIS
  • 5.6.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025
  • 5.6.2 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY REGION, 2025
• 5.7 KEY CONFERENCES & EVENTS
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT/FUNDING ACTIVITY
• 5.10 CASE STUDY ANALYSIS
• 5.11 IMPACT OF 2025 US TARIFFS ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Hospitals & diagnostic centers
    • 5.11.5.2 Academic & government research institutes
    • 5.11.5.3 Pharmaceutical & biotechnology companies
    • 5.11.5.4 Contract research organizations (CROs)
    • 5.11.5.5 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Silica membrane/spin column purification
    • 6.1.1.2 Magnetic bead-based purification
    • 6.1.1.3 Reagent-based extraction/organic extraction
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Sample lysis & homogenization technologies
    • 6.1.2.2 Centrifugation & vacuum manifold systems
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 PCR & qPCR technologies
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCT/TECHNOLOGY PATENTS, 2015-2025
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
  • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
• 6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGULATORY LANDSCAPE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK/KEY REGULATIONS
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
      • 7.1.2.2.1 Germany
      • 7.1.2.2.2 France
      • 7.1.2.2.3 UK
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 Japan
      • 7.1.2.3.2 China
      • 7.1.2.3.3 India
      • 7.1.2.3.4 South Korea
    • 7.1.2.4 Latin America
      • 7.1.2.4.1 Brazil
    • 7.1.2.5 Middle East
      • 7.1.2.5.1 Saudi Arabia
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 KITS
  • 9.2.1 KITS TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD
• 9.3 REAGENTS
  • 9.3.1 AVAILABILITY OF READY-TO-USE REAGENTS TO DRIVE GROWTH
• 9.4 INSTRUMENTS
  • 9.4.1 AUTOMATIC INSTRUMENTS
    • 9.4.1.1 Benefits of automatic instruments to drive growth
  • 9.4.2 MANUAL INSTRUMENTS
    • 9.4.2.1 Growing demand for nucleic acid isolation and purification in research and clinical applications to drive growth

10 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD

• 10.1 INTRODUCTION
• 10.2 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION
  • 10.2.1 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
• 10.3 REAGENT-BASED ISOLATION AND PURIFICATION
  • 10.3.1 REAGENT-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER STEADY GROWTH DURING FORECAST PERIOD
• 10.4 COLUMN-BASED ISOLATION AND PURIFICATION
  • 10.4.1 GROWING POPULARITY OF COLUMN-BASED ISOLATION AND PURIFICATION IN CURRENT KITS TO BOOST MARKET
• 10.5 OTHER ISOLATION AND PURIFICATION METHODS

11 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 PLASMID DNA ISOLATION AND PURIFICATION
  • 11.2.1 PLASMID DNA ISOLATION AND PURIFICATION TO ACCOUNT FOR LARGEST SHARE OF MARKET
• 11.3 TOTAL RNA ISOLATION AND PURIFICATION
  • 11.3.1 WIDE USE OF TOTAL RNA ISOLATION AND PURIFICATION FOR RESEARCH AND DIAGNOSTIC APPLICATIONS TO BOOST MARKET
• 11.4 GENOMIC DNA ISOLATION AND PURIFICATION
  • 11.4.1 IMPORTANCE OF GENOMIC DNA ISOLATION IN GENETIC-BASED TESTS TO SUPPORT GROWTH
• 11.5 MESSENGER RNA ISOLATION AND PURIFICATION
  • 11.5.1 ROLE PLAYED BY MESSENGER RNA ISOLATION AND PURIFICATION IN GENE EXPRESSION AND TRANSCRIPTOMICS TO DRIVE GROWTH
• 11.6 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION
  • 11.6.1 ABILITY OF CIRCULATING NAIP TO ENABLE COLLECTION OF GENETIC INFORMATION FROM BODY FLUIDS TO BOOST ADOPTION
• 11.7 MICRORNA ISOLATION AND PURIFICATION
  • 11.7.1 GROWING APPLICATIONS OF MICRORNA ISOLATION AND PURIFICATION IN DRUG DEVELOPMENT RESEARCH TO FUEL GROWTH
• 11.8 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES

12 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE

• 12.1 INTRODUCTION
• 12.2 CELLULAR SAMPLES
  • 12.2.1 WBCS
    • 12.2.1.1 Strong demand from routine blood-based genomics and diagnostic testing workflows to boost market
  • 12.2.2 CULTURED CELLS
    • 12.2.2.1 Core segment supporting drug discovery, cell biology, and biopharma R&D applications
  • 12.2.3 BACTERIAL
    • 12.2.3.1 Rising adoption in infectious disease, microbiome, and environmental testing workflows to fuel market growth
  • 12.2.4 OTHER CELLULAR SAMPLES
• 12.3 PRESERVED TISSUE SAMPLES
  • 12.3.1 FRESH/FROZEN TISSUES
    • 12.3.1.1 Preferred for high-quality nucleic acid recovery in research and translational studies
  • 12.3.2 FFPE (FORMALIN-FIXED PARAFFIN-EMBEDDED)
    • 12.3.2.1 Fastest-growing segment fueled by increasing use of archived clinical samples in oncology
  • 12.3.3 OTHER PRESERVED TISSUE SAMPLES
• 12.4 CELL-FREE SAMPLES
  • 12.4.1 CFDNA/CTDNA
    • 12.4.1.1 Key growth driver enabling liquid biopsy and real-time disease monitoring
  • 12.4.2 OTHER CELL-FREE SAMPLES
• 12.5 OTHER SAMPLES

13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION

• 13.1 INTRODUCTION
• 13.2 DIAGNOSTICS
  • 13.2.1 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD
• 13.3 DRUG DISCOVERY & DEVELOPMENT
  • 13.3.1 POTENTIAL OF NAIP TO HELP IN DEVELOPMENT OF DRUGS FOR RARE DISEASES TO BOOST MARKET
• 13.4 PERSONALIZED MEDICINE
  • 13.4.1 RISING INCIDENCE OF CANCER AND INCREASING RESEARCH AND FUNDING TO DRIVE GROWTH
• 13.5 AGRICULTURE & ANIMAL RESEARCH
  • 13.5.1 FAVORABLE FUNDING SCENARIO TO SUPPORT MARKET GROWTH
• 13.6 OTHER APPLICATIONS

14 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 HOSPITALS & DIAGNOSTIC CENTERS
  • 14.2.1 RISING FOCUS ON PERSONALIZED MEDICINE IN HOSPITALS TO DRIVE MARKET GROWTH
• 14.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
  • 14.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USAGE OF NUCLEIC ACID ISOLATION AND PURIFICATION SYSTEMS
• 14.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 14.4.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS AND RELATED AREAS TO DRIVE SEGMENT GROWTH
• 14.5 CONTRACT RESEARCH ORGANIZATIONS
  • 14.5.1 CONTRACT RESEARCH ORGANIZATIONS TO REGISTER STEADY GROWTH DURING FORECAST PERIOD
• 14.6 OTHER END USERS

15 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 Government and private funding to support market growth
  • 15.2.2 CANADA
    • 15.2.2.1 Growing investments in genomics to boost market demand
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Germany to dominate market in Europe
  • 15.3.2 UK
    • 15.3.2.1 Government support for research through investments, funds, and grants to support market growth
  • 15.3.3 FRANCE
    • 15.3.3.1 Increasing number of established biotech facilities to drive market growth
  • 15.3.4 ITALY
    • 15.3.4.1 Government support to drive market growth in Italy
  • 15.3.5 SPAIN
    • 15.3.5.1 High adoption of advanced diagnostic technologies to drive market growth in Spain
  • 15.3.6 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Strong domestic genomics scale and tightening IVD framework to drive NAIP adoption
  • 15.4.2 JAPAN
    • 15.4.2.1 Whole-genome medicine and structured clinical implementation to support premium NAIP demand
  • 15.4.3 INDIA
    • 15.4.3.1 National genomics initiatives and rising domestic manufacturing to expand NAIP opportunities
  • 15.4.4 AUSTRALIA
    • 15.4.4.1 Precision health funding and rare-disease genomics to support advanced NAIP workflows
  • 15.4.5 SOUTH KOREA
    • 15.4.5.1 Support from governments to drive market in region
  • 15.4.6 REST OF ASIA PACIFIC (ROAPAC)
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Brazil to dominate LATAM market
  • 15.5.2 MEXICO
    • 15.5.2.1 Favorable trade agreements to support imports and improve access to NAIP instruments in Mexico
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 GCC COUNTRIES
    • 15.6.1.1 Saudi Arabia
      • 15.6.1.1.1 National genomics strategy and precision medicine expansion to accelerate NAIP demand
    • 15.6.1.2 UAE
      • 15.6.1.2.1 Molecular lab standardization and genomics-led healthcare investment to strengthen NAIP adoption
    • 15.6.1.3 Rest of GCC Countries
  • 15.6.2 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 GOVERNMENT SUPPORT FOR RESEARCH STUDIES TO FUEL GROWTH

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
• 16.3 REVENUE ANALYSIS, 2021-2025
• 16.4 MARKET SHARE ANALYSIS, 2025
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Product footprint
    • 16.5.5.4 Method footprint
    • 16.5.5.5 Application footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 16.6.5.1 List of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of key startups/SMEs
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.1 FINANCIAL METRICS
  • 16.7.2 COMPANY VALUATION
• 16.8 BRAND/PRODUCT COMPARISON
  • 16.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES
  • 16.9.2 DEALS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 THERMO FISHER SCIENTIFIC INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product launches
      • 17.1.1.3.2 Expansions
      • 17.1.1.3.3 Other developments
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 QIAGEN N.V.
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches
      • 17.1.2.3.2 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 MERCK KGAA
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Other developments
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 DANAHER CORPORATION
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Deals
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses & competitive threats
  • 17.1.6 PROMEGA CORPORATION
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Deals
  • 17.1.7 AGILENT TECHNOLOGIES, INC.
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Other Developments
  • 17.1.8 BIO-RAD LABORATORIES, INC.
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products offered
  • 17.1.9 ILLUMINA, INC.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches
  • 17.1.10 TAKARA BIO INC.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products offered
  • 17.1.11 NEW ENGLAND BIOLABS
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Product launches
  • 17.1.12 A&A BIOTECHNOLOGY
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products offered
  • 17.1.13 REVVITY INC.
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products offered
  • 17.1.14 BIONEER CORPORATION
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products offered
  • 17.1.15 HIMEDIA LABORATORIES PRIVATE LIMITED
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products offered
• 17.2 OTHER PLAYERS
  • 17.2.1 KILPEST INDIA LIMITED
  • 17.2.2 APICAL SCIENTIFIC SDN. BHD.
  • 17.2.3 ENDRESS+HAUSER GROUP SERVICES AG
  • 17.2.4 GENAXXON BIOSCIENCE GMBH
  • 17.2.5 LGC BIOSEARCH TECHNOLOGIES
  • 17.2.6 ZYMO RESEARCH CORPORATION
  • 17.2.7 NORGEN BIOTEK CORP.
  • 17.2.8 OMEGA BIO-TEK, INC.
  • 17.2.9 FAVORGEN BIOTECH CORPORATION
  • 17.2.10 TIANGEN BIOTECH(BEIJING)CO., LTD.
  • 17.2.11 AUTOGEN INC.
  • 17.2.12 PCR BIOSYSTEMS
  • 17.2.13 BIOGENUIX
  • 17.2.14 MP BIOMEDICALS
  • 17.2.15 NANJING VAZYME BIOTECH CO., LTD.

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH DATA
  • 18.1.1 SECONDARY DATA
    • 18.1.1.1 Key data from secondary sources
  • 18.1.2 PRIMARY DATA
    • 18.1.2.1 Key data from primary sources
    • 18.1.2.2 Key primary participants
    • 18.1.2.3 Breakdown of primary interviews
    • 18.1.2.4 Key industry insights
• 18.2 MARKET SIZE ESTIMATION
  • 18.2.1 SEGMENTAL MARKET SIZE ESTIMATION
• 18.3 MARKET GROWTH RATE PROJECTIONS
• 18.4 FACTOR ANALYSIS
• 18.5 DATA TRIANGULATION
• 18.6 RESEARCH ASSUMPTIONS
• 18.7 RESEARCH LIMITATIONS & RISK ASSESSMENT
• 18.8 SRISK ASSESSMENT

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 CUSTOMIZATION OPTIONS
• 19.4 RELATED REPORTS
• 19.5 AUTHOR DETAILS